Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAPSS: Saxagliptin in T2DM Patients Undergoing CABG
NCT01765270Phase 4Terminated
- Sponsor
- Duke University
- Start
- Mar 2013
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of saxagliptin in type 2 diabetes mellitus (T2DM), sponsored by Duke University. Started Mar 2013; status: terminated.
02
Drugs
saxagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01765270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01765270.